All the news Showing 10 of 23 articles from: AASLD 2013Get an RSS feed of these articles Show All news infohep newsEditors' picks from other sources HIV Faldaprevir plus pegylated interferon/ribavirin leads to early sustained response in people with HIV and HCV co-infection Liz Highleyman / 14 November 2013 The hepatitis C protease inhibitor faldaprevir plus pegylated interferon and ribavirin improved 4-week sustained response rates for HIV-positive people with genotype 1 hepatitis C co-infection in the STARTVerso4 trial, according to a ... Protease inhibitors Faldaprevir effective across patient sub-groups with several baseline characteristics associated with treatment outcomes Michael Carter / 14 November 2013 The experimental hepatitis C virus (HCV) protease inhibitor faldaprevir is efficacious across a range of subgroups of patients with genotype 1 infection, according to research presented to the recent Liver Meeting 2013, the ... Interferon-free regimens Fixed-dose sofosbuvir/ledipasvir with or without ribavirin cures most genotype 1 hepatitis C patients, LONESTAR study shows Liz Highleyman / 13 November 2013 At least 95% of newly treated people with genotype 1 hepatitis C and prior non-responders achieved sustained virological response using a fixed-dose combination of sofosbuvir plus ledipasvir, with or without ribavirin, according to ... Antiviral therapy Hepatitis B treatment with entecavir or tenofovir lowers, but does not eliminate, liver cancer risk Liz Highleyman / 11 November 2013 Long-term treatment with entecavir can reduce the likelihood that people with chronic hepatitis B will develop hepatocellular carcinoma, according to findings presented last week at The Liver Meeting 2013, the 64th annual meeting ... Treatment in liver transplanted Sofosbuvir taken before or after liver transplant reduces hepatitis C recurrence Liz Highleyman / 08 November 2013 An interferon-free combination of sofosbuvir plus ribavirin administered before liver transplantation prevented hepatitis C recurrence in nearly two-thirds of patients, while the same regimen led to early viral clearance in three-quarters of those ... Treatment for people living with HIV and HCV Sofosbuvir + ribavirin produces sustained response in 76% of genotype 1 HIV/HCV co-infected people Liz Highleyman / 08 November 2013 An interferon-free regimen of sofosbuvir plus ribavirin taken for 24 weeks cured hepatitis C infection in three quarters of previously untreated HIV-positive people co-infected with hepatitis C virus (HCV) genotype 1, while ... Interferon-free regimens BMS interferon-free combination cures over 90% of genotype 1 hepatitis C in 12 weeks Keith Alcorn / 06 November 2013 A combination of three direct-acting antivirals developed by Bristol-Myers Squibb cured chronic hepatitis C infection in over 90% of previously untreated patients in a mid-stage study, Gregory Everson of the University of Colorado ... Simeprevir + sofosbuvir produces high sustained response rates for hard-to-treat patients in COSMOS trial Liz Highleyman / 06 November 2013 A 12-week all-oral combination of simeprevir plus sofosbuvir led to sustained virological response (SVR12) in 93% of genotype 1 prior null responders with mild-to-moderate liver fibrosis, working as well as a longer course ... Interferon-free regimens In ELECTRON trial, 100% of hard-to-treat patients cured with sofosbuvir/ledipasvir plus ribavirin or GS-9669 Liz Highleyman / 05 November 2013 Interferon-free regimens of sofosbuvir and ledipasvir plus either ribavirin or GS-9669 taken for 12 weeks produced sustained response in 100% of treatment-experienced people with genotype 1 chronic hepatitis C virus (HCV) with advanced ... Interferon-free regimens AbbVie's two-drug, interferon-free combination cures genotype 1b hepatitis C infection in 95% Keith Alcorn / 05 November 2013 A two-drug combination of direct-acting antivirals developed by AbbVie achieved sustained virologic response in 95% of previously untreated patients with genotype 1b hepatitis C infection after 12 weeks of treatment, without the need ... ← Prev123Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive